CERo Therapeutics (CERO) Stock Price, News & Analysis

Company Overview

CERo Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing engineered cell therapies for the treatment of cancer. The company focuses on therapies designed to combine the tumor-targeting capabilities of T cells with the engulfing, or phagocytic, activity typically associated with cells of the innate immune system.

CERo’s technology platform is intended to create “CER-T” cells that can recognize and attack malignant cells through multiple mechanisms. Its research and development programs are aimed at hematologic cancers and potentially solid tumors, with lead development efforts focused on acute myeloid leukemia and other difficult-to-treat blood cancers.

The company’s lead investigational program, CER-1236, is being developed as an engineered cell therapy for patients with relapsed or refractory disease. Like other early-stage biotechnology programs, CERo’s candidates remain subject to clinical testing and regulatory review, and their safety and effectiveness have not been established for general use.

CERo Therapeutics became a publicly traded company through a business combination with Phoenix Biotech Acquisition Corp. The company is based in the United States and conducts its development activities through its biotechnology and cell-therapy operations.

Key Stats

• Today's Range: $0.0082 to $0.0094
• 50-Day Range: $0.0080 to $0.0158
• 52-Week Range: $0.01 to $4.40
• Volume: 1.11 million shs
• Average Volume: 656,807 shs
• Market Capitalization: $637.52 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Hold

CERo Therapeutics Stock Analysis - MarketRank™

CERo Therapeutics scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

CERo Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

CERo Therapeutics has a consensus price target of $30.00, representing about 336,978.7% upside from its current price of $0.01.

Amount of Analyst Coverage

CERo Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CERo Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CERo Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CERO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CERo Therapeutics does not currently pay a dividend.

Dividend Growth

CERo Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.22

News Sentiment

CERo Therapeutics has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for CERo Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for CERO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added CERo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CERo Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.36% of the stock of CERo Therapeutics is held by insiders.

Percentage Held by Institutions

29.64% of the stock of CERo Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/22/2025
• Today: 10/11/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CERO
• Previous Symbol: NASDAQ:CERO
• CIK: 1870404
• Web: www.cero.bio
• Phone: (650) 407-2376
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CERo Therapeutics: $30.00
• High Price Target: $30.00
• Low Price Target: $30.00
• Potential Upside/Downside: +336,978.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.30 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -209.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.56
• Quick Ratio: 0.56

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($41.98) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 71,631,000
• Free Float: 1,052,000
• Market Cap: $637.52 thousand
• Optionable: N/A
• Beta: 0.19